OKYO Pharma Limited Ordinary Shares - OKYO STOCK NEWS

RedChip Companies announces the airing of interviews with MUSQ Global Music Industry ETF (NYSE:MUSQ) and OKYO Pharma on Bloomberg TV. David Schulhof, MUSQ's Founder and CEO, discusses how their ETF provides exposure to the global music ecosystem through the MUSQ Global Music Industry Index (MUSQIX), covering music streaming, content, distribution, live events, radio, and equipment. Goldman Sachs projects industry revenue to reach $163.7B by 2030.

OKYO Pharma's CEO Gary Jacob discusses their Phase 2 clinical trial of OK-101, a novel non-opioid topical treatment for neuropathic corneal pain (NCP). The trial, initiated October 16, 2024, at Tufts Medical Center, aims to evaluate OK-101's effectiveness in treating NCP caused by dry eye disease, surgery, or infections.

OKYO Pharma (NASDAQ: OKYO) announces its participation in the 10th International Tear Film & Ocular Surface Society Conference in Venice, Italy from October 30 to November 2, 2024. The company will present results from their dry eye disease trial and discuss their ongoing Phase 2 trial of OK-101 for Neuropathic Corneal Pain treatment at Tufts Medical Center.

Chief Scientific Officer Dr. Raj Patil will present 'Efficacy and Safety Results of First-in-Human Phase 2 Trial of OK-101 in Dry Eye Patients' during Poster Session III on November 2, 2024. The company aims to develop treatments for both neuropathic corneal pain, which currently lacks FDA-approved therapy, and inflammatory dry eye disease, representing a multi-billion-dollar market opportunity.

OKYO Pharma (NASDAQ: OKYO) has initiated its Phase 2 clinical trial for OK-101, announcing the first patient dosing in a study targeting Neuropathic Corneal Pain (NCP). The trial is designed as a double-masked, randomized, 12-week placebo-controlled study involving 48 patients with NCP confirmed via confocal microscopy. OK-101 is a novel, non-opioid therapeutic candidate and the first drug to receive FDA IND approval specifically for NCP treatment. The study is being conducted at a single center under the leadership of Dr. Pedram Hamrah at Tufts Medical Center, a leading expert in NCP treatment and research.

OKYO Pharma has initiated a Phase 2 clinical trial for OK-101 to treat Neuropathic Corneal Pain (NCP), a rare ocular condition with no FDA-approved treatments. The trial, led by Dr. Pedram Hamrah at Tufts Medical Center, will enroll 48 patients in a 12-week, double-masked, randomized, placebo-controlled study. The primary endpoint is pain relief measured by the Visual Analog Scale (VAS).

OK-101 recently showed promising results in a Phase 2 dry eye disease trial, demonstrating statistically significant improvements in symptoms like stinging/burning and ocular pain. It also reduced neuropathic corneal pain in a mouse model. OKYO Pharma is the first company to receive FDA approval for an Investigational New Drug (IND) application for NCP, which is listed as an orphan disease by the National Organization for Rare Disorders (NORD).

OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing innovative ocular therapies, has announced a significant insider purchase. Gabriele Cerrone, the Executive Chairman, through Panetta Partners , acquired 50,000 ordinary shares at $1.03 per share on NASDAQ. This transaction has increased Cerrone's total shareholding to 9,851,570 shares, representing 29.12% of the company's issued share capital.

OKYO Pharma specializes in treatments for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), an ocular condition currently lacking FDA-approved therapies. This insider purchase may signal confidence in the company's future prospects and ongoing clinical developments.

OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on innovative ocular therapies, has announced a significant insider purchase. The company's Executive Chairman, Gabriele Cerrone, through Panetta Partners , has acquired 80,000 ordinary shares at $1.15 per share on NASDAQ. This acquisition has increased Cerrone's total shareholding to 9,801,570 shares, representing 28.97% of the company's issued share capital.

OKYO Pharma specializes in developing treatments for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), an ocular condition currently lacking FDA-approved therapies. This insider purchase may signal confidence in the company's future prospects and ongoing clinical developments.

OKYO Pharma (NASDAQ: OKYO) has been granted U.S. Patent No. 12,053,501 for its OK-101 drug, covering methods for treating symptoms of dry eye disease (DED). The patent, issued on August 6th, specifically addresses the use of OK-101 to treat irritated, burning eyes and blurred vision in DED patients. This development strengthens OKYO's intellectual property position in the multi-billion-dollar DED market.

OKYO Pharma is a clinical-stage biopharmaceutical company focusing on innovative ocular therapies for inflammatory DED and neuropathic corneal pain (NCP). The company's CEO, Dr. Gary S. Jacob, emphasized the importance of this patent in advancing their efforts to address unmet medical needs in ocular pain and inflammation treatment.

OKYO Pharma (NASDAQ: OKYO) announced that an interview with CEO Dr. Gary S. Jacob will air on Bloomberg TV's The RedChip Small Stocks, Big Money™ show on August 24, 2024, at 7 p.m. ET. The interview will provide a corporate update on OKYO's development of innovative therapies for Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP).

OKYO's lead candidate, OK-101, a lipid-conjugated chemerin peptide, has shown promising results in a recent Phase 2 trial for DED, demonstrating improvements in symptoms and signs within 15 days with a favorable safety profile. The company is also targeting NCP, an ocular condition without FDA-approved treatments. OKYO has patent protection through 2039 and an experienced management team with a track record of successful clinical development and FDA approvals.

OKYO Pharma and SolarMax Technology are set to feature on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, August 24, at 7 p.m. ET. The show, available in an estimated 73 million U.S. homes, will air exclusive interviews with the CEOs of both companies.

OKYO Pharma (Nasdaq: OKYO), a clinical-stage biopharmaceutical company, is developing innovative therapies for Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP). Their lead candidate, OK-101, showed promising results in a recent Phase 2 trial for DED, demonstrating improvements in symptoms and signs within 15 days.

SolarMax Technology (Nasdaq: SMXT), founded in 2008, has completed over 15,000 solar installations. The company is expanding its commercial solar development services in the U.S. market, with recent large-scale projects announced in Las Vegas and San Jose.